Fluorescence:Article Title: Vaccines give written description guidance.
Article Snippet: .. WO 20050032139 Rigel Pharmaceuticals Fluorescent assay for detecting modulators of ubiquitin ligase; involves tagging ubiquitin with a fluorescent label and incubating with E2 and E3 ligases, and quantifying the amount of tagged ubiquitin bound to E3 ligase FR 2867783 Cytomics Systems Method for screening for modulators of ubiquitylation of IκBα by ubiquitin ligase complex incorporating β-TRCP; useful for treating inflammation and autoimmune diseases FR 2859733 CRNS Claims a cell-based screen for ubiquitin hydrolase modulators; can identify compounds that affect disorders associated with UPS dysfunction such as cancer and neurodegenerative disorders WO 200520922 State University of New York Claims a screening method for identifying compounds that modulate FBP1 ubiquitin ligase by measuring the activity of FBP1 relative to FBP5 WO 200420979 Rigel Pharmaceuticals Claims the use of ubiquitin ligation pathway components for identifying compounds that modulate cell-cycle activity, and a method for inducing cell-cycle arrest WO 200388910 Rigel Pharmaceuticals Claims methods for identifying compounds that modulate cell-cycle arrest by acting on target proteins including ubiquitin-conjugating enzyme E2 variant WO 200438036 Rigel Pharmaceuticals Method for identifying a compound that modulates inflammation by affecting the ubiquitylation pathway; useful for the diagnosis, prevention or treatment of UPS-associated disorders WO 200012679 State University of New York Claims nucleic-acid sequences for substrate-targeting domains of ubiquitin ligases with F-box motifs; useful for screening for compounds that modulate the UPS WO 200255665 Pagano, M. et al. (State University of New York) Method for screening compounds for treating cancer, infections or immune disorders by detecting a change in the activity of SKP2 WO 200617855 Geng, Y. ..
Ubiquitin Proteomics:Article Title: Vaccines give written description guidance.
Article Snippet: .. WO 20050032139 Rigel Pharmaceuticals Fluorescent assay for detecting modulators of ubiquitin ligase; involves tagging ubiquitin with a fluorescent label and incubating with E2 and E3 ligases, and quantifying the amount of tagged ubiquitin bound to E3 ligase FR 2867783 Cytomics Systems Method for screening for modulators of ubiquitylation of IκBα by ubiquitin ligase complex incorporating β-TRCP; useful for treating inflammation and autoimmune diseases FR 2859733 CRNS Claims a cell-based screen for ubiquitin hydrolase modulators; can identify compounds that affect disorders associated with UPS dysfunction such as cancer and neurodegenerative disorders WO 200520922 State University of New York Claims a screening method for identifying compounds that modulate FBP1 ubiquitin ligase by measuring the activity of FBP1 relative to FBP5 WO 200420979 Rigel Pharmaceuticals Claims the use of ubiquitin ligation pathway components for identifying compounds that modulate cell-cycle activity, and a method for inducing cell-cycle arrest WO 200388910 Rigel Pharmaceuticals Claims methods for identifying compounds that modulate cell-cycle arrest by acting on target proteins including ubiquitin-conjugating enzyme E2 variant WO 200438036 Rigel Pharmaceuticals Method for identifying a compound that modulates inflammation by affecting the ubiquitylation pathway; useful for the diagnosis, prevention or treatment of UPS-associated disorders WO 200012679 State University of New York Claims nucleic-acid sequences for substrate-targeting domains of ubiquitin ligases with F-box motifs; useful for screening for compounds that modulate the UPS WO 200255665 Pagano, M. et al. (State University of New York) Method for screening compounds for treating cancer, infections or immune disorders by detecting a change in the activity of SKP2 WO 200617855 Geng, Y. ..
Activity Assay:Article Title: Vaccines give written description guidance.
Article Snippet: .. WO 20050032139 Rigel Pharmaceuticals Fluorescent assay for detecting modulators of ubiquitin ligase; involves tagging ubiquitin with a fluorescent label and incubating with E2 and E3 ligases, and quantifying the amount of tagged ubiquitin bound to E3 ligase FR 2867783 Cytomics Systems Method for screening for modulators of ubiquitylation of IκBα by ubiquitin ligase complex incorporating β-TRCP; useful for treating inflammation and autoimmune diseases FR 2859733 CRNS Claims a cell-based screen for ubiquitin hydrolase modulators; can identify compounds that affect disorders associated with UPS dysfunction such as cancer and neurodegenerative disorders WO 200520922 State University of New York Claims a screening method for identifying compounds that modulate FBP1 ubiquitin ligase by measuring the activity of FBP1 relative to FBP5 WO 200420979 Rigel Pharmaceuticals Claims the use of ubiquitin ligation pathway components for identifying compounds that modulate cell-cycle activity, and a method for inducing cell-cycle arrest WO 200388910 Rigel Pharmaceuticals Claims methods for identifying compounds that modulate cell-cycle arrest by acting on target proteins including ubiquitin-conjugating enzyme E2 variant WO 200438036 Rigel Pharmaceuticals Method for identifying a compound that modulates inflammation by affecting the ubiquitylation pathway; useful for the diagnosis, prevention or treatment of UPS-associated disorders WO 200012679 State University of New York Claims nucleic-acid sequences for substrate-targeting domains of ubiquitin ligases with F-box motifs; useful for screening for compounds that modulate the UPS WO 200255665 Pagano, M. et al. (State University of New York) Method for screening compounds for treating cancer, infections or immune disorders by detecting a change in the activity of SKP2 WO 200617855 Geng, Y. ..
Ligation:Article Title: Vaccines give written description guidance.
Article Snippet: .. WO 20050032139 Rigel Pharmaceuticals Fluorescent assay for detecting modulators of ubiquitin ligase; involves tagging ubiquitin with a fluorescent label and incubating with E2 and E3 ligases, and quantifying the amount of tagged ubiquitin bound to E3 ligase FR 2867783 Cytomics Systems Method for screening for modulators of ubiquitylation of IκBα by ubiquitin ligase complex incorporating β-TRCP; useful for treating inflammation and autoimmune diseases FR 2859733 CRNS Claims a cell-based screen for ubiquitin hydrolase modulators; can identify compounds that affect disorders associated with UPS dysfunction such as cancer and neurodegenerative disorders WO 200520922 State University of New York Claims a screening method for identifying compounds that modulate FBP1 ubiquitin ligase by measuring the activity of FBP1 relative to FBP5 WO 200420979 Rigel Pharmaceuticals Claims the use of ubiquitin ligation pathway components for identifying compounds that modulate cell-cycle activity, and a method for inducing cell-cycle arrest WO 200388910 Rigel Pharmaceuticals Claims methods for identifying compounds that modulate cell-cycle arrest by acting on target proteins including ubiquitin-conjugating enzyme E2 variant WO 200438036 Rigel Pharmaceuticals Method for identifying a compound that modulates inflammation by affecting the ubiquitylation pathway; useful for the diagnosis, prevention or treatment of UPS-associated disorders WO 200012679 State University of New York Claims nucleic-acid sequences for substrate-targeting domains of ubiquitin ligases with F-box motifs; useful for screening for compounds that modulate the UPS WO 200255665 Pagano, M. et al. (State University of New York) Method for screening compounds for treating cancer, infections or immune disorders by detecting a change in the activity of SKP2 WO 200617855 Geng, Y. ..
Variant Assay:Article Title: Vaccines give written description guidance.
Article Snippet: .. WO 20050032139 Rigel Pharmaceuticals Fluorescent assay for detecting modulators of ubiquitin ligase; involves tagging ubiquitin with a fluorescent label and incubating with E2 and E3 ligases, and quantifying the amount of tagged ubiquitin bound to E3 ligase FR 2867783 Cytomics Systems Method for screening for modulators of ubiquitylation of IκBα by ubiquitin ligase complex incorporating β-TRCP; useful for treating inflammation and autoimmune diseases FR 2859733 CRNS Claims a cell-based screen for ubiquitin hydrolase modulators; can identify compounds that affect disorders associated with UPS dysfunction such as cancer and neurodegenerative disorders WO 200520922 State University of New York Claims a screening method for identifying compounds that modulate FBP1 ubiquitin ligase by measuring the activity of FBP1 relative to FBP5 WO 200420979 Rigel Pharmaceuticals Claims the use of ubiquitin ligation pathway components for identifying compounds that modulate cell-cycle activity, and a method for inducing cell-cycle arrest WO 200388910 Rigel Pharmaceuticals Claims methods for identifying compounds that modulate cell-cycle arrest by acting on target proteins including ubiquitin-conjugating enzyme E2 variant WO 200438036 Rigel Pharmaceuticals Method for identifying a compound that modulates inflammation by affecting the ubiquitylation pathway; useful for the diagnosis, prevention or treatment of UPS-associated disorders WO 200012679 State University of New York Claims nucleic-acid sequences for substrate-targeting domains of ubiquitin ligases with F-box motifs; useful for screening for compounds that modulate the UPS WO 200255665 Pagano, M. et al. (State University of New York) Method for screening compounds for treating cancer, infections or immune disorders by detecting a change in the activity of SKP2 WO 200617855 Geng, Y. ..
Biomarker Discovery:Article Title: Vaccines give written description guidance.
Article Snippet: .. WO 20050032139 Rigel Pharmaceuticals Fluorescent assay for detecting modulators of ubiquitin ligase; involves tagging ubiquitin with a fluorescent label and incubating with E2 and E3 ligases, and quantifying the amount of tagged ubiquitin bound to E3 ligase FR 2867783 Cytomics Systems Method for screening for modulators of ubiquitylation of IκBα by ubiquitin ligase complex incorporating β-TRCP; useful for treating inflammation and autoimmune diseases FR 2859733 CRNS Claims a cell-based screen for ubiquitin hydrolase modulators; can identify compounds that affect disorders associated with UPS dysfunction such as cancer and neurodegenerative disorders WO 200520922 State University of New York Claims a screening method for identifying compounds that modulate FBP1 ubiquitin ligase by measuring the activity of FBP1 relative to FBP5 WO 200420979 Rigel Pharmaceuticals Claims the use of ubiquitin ligation pathway components for identifying compounds that modulate cell-cycle activity, and a method for inducing cell-cycle arrest WO 200388910 Rigel Pharmaceuticals Claims methods for identifying compounds that modulate cell-cycle arrest by acting on target proteins including ubiquitin-conjugating enzyme E2 variant WO 200438036 Rigel Pharmaceuticals Method for identifying a compound that modulates inflammation by affecting the ubiquitylation pathway; useful for the diagnosis, prevention or treatment of UPS-associated disorders WO 200012679 State University of New York Claims nucleic-acid sequences for substrate-targeting domains of ubiquitin ligases with F-box motifs; useful for screening for compounds that modulate the UPS WO 200255665 Pagano, M. et al. (State University of New York) Method for screening compounds for treating cancer, infections or immune disorders by detecting a change in the activity of SKP2 WO 200617855 Geng, Y. ..
|
